clobazam has been researched along with Chronic Pain in 2 studies
Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.
Chronic Pain: Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this randomized, double blinded, placebo controlled cross-over study, patients with chronic low back pain are randomly assigned to imipramine, oxycodone or clobazam versus active placebo." | 5.20 | Linking altered central pain processing and genetic polymorphism to drug efficacy in chronic low back pain. ( Arendt-Nielsen, L; Curatolo, M; Juni, P; Schliessbach, J; Siegenthaler, A; Vuilleumier, PH; Zeilhofer, HU, 2015) |
| "Chronic pain is frequently associated with hypersensitivity of the nervous system, and drugs that increase central inhibition are therefore a potentially effective treatment." | 2.84 | Analgesic effect of clobazam in chronic low-back pain but not in experimentally induced pain. ( Arendt-Nielsen, L; Bütikofer, L; Curatolo, M; Juni, P; Limacher, A; Schliessbach, J; Siegenthaler, A; Vuilleumier, PH; Zeilhofer, HU, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schliessbach, J | 2 |
| Vuilleumier, PH | 2 |
| Siegenthaler, A | 2 |
| Bütikofer, L | 1 |
| Limacher, A | 1 |
| Juni, P | 2 |
| Zeilhofer, HU | 2 |
| Arendt-Nielsen, L | 2 |
| Curatolo, M | 2 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Linking Altered Central Pain Processing and Genetic Polymorphism to Drug Efficacy in Chronic Low Back Pain[NCT01179828] | Phase 3 | 150 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for clobazam and Chronic Pain
| Article | Year |
|---|---|
Analgesic effect of clobazam in chronic low-back pain but not in experimentally induced pain.
Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Chronic Pain; Clobazam; Cross-Over Studies; Double-Bl | 2017 |
Linking altered central pain processing and genetic polymorphism to drug efficacy in chronic low back pain.
Topics: Adolescent; Adult; Aged; Analgesics; Benzodiazepines; Chronic Pain; Clinical Protocols; Clobazam; Cr | 2015 |